Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Checkmate Pharmaceuticals Inc (CMPI)

Checkmate Pharmaceuticals Inc (CMPI)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 231,399
  • Shares Outstanding, K 22,038
  • Annual Sales, $ 0 K
  • Annual Income, $ -61,410 K
  • 60-Month Beta -4.84
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 4.20
Trade CMPI with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -2.92
  • Most Recent Earnings $-0.73 on 05/12/22
  • Latest Earnings Date N/A
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/22
See More
  • Average Estimate -0.75
  • Number of Estimates 1
  • High Estimate -0.75
  • Low Estimate -0.75
  • Prior Year -0.88
  • Growth Rate Est. (year over year) +14.77%

Price Performance

See More
Period Period Low Period High Performance
1-Month
10.34 +1.55%
on 05/11/22
10.50 unch
on 05/27/22
+0.11 (+1.06%)
since 04/27/22
3-Month
2.41 +335.68%
on 04/18/22
10.50 unch
on 05/27/22
+7.65 (+268.42%)
since 02/25/22
52-Week
2.00 +425.00%
on 01/27/22
10.50 unch
on 05/27/22
+3.82 (+57.19%)
since 05/27/21

Most Recent Stories

More News
University of Iowa Holden Comprehensive Cancer Center Presents Preliminary Data from Clinical Trial of Vidutolimod at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting

CAMBRIDGE, Mass., May 26, 2022 (GLOBE NEWSWIRE) -- Checkmate Pharmaceuticals, Inc. (NASDAQ: CMPI) (“Checkmate”), a clinical stage biotechnology...

CMPI : 10.50 (+0.19%)
CHECKMATE PHARMACEUTICALS INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Checkmate Pharmaceuticals, Inc. - CMPI

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Checkmate Pharmaceuticals, Inc. (NasdaqGM:...

CMPI : 10.50 (+0.19%)
REGN : 883.20 (-0.84%)
Checkmate Pharmaceuticals Announces First Quarter 2022 Financial Results and Provides Business Update

CAMBRIDGE, Mass., May 12, 2022 (GLOBE NEWSWIRE) -- Checkmate Pharmaceuticals, Inc. (Nasdaq: CMPI) (“Checkmate”), a clinical stage biopharmaceutical...

CMPI : 10.50 (+0.19%)
CHECKMATE PHARMACEUTICALS INVESTOR ALERT by The Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Checkmate Pharmaceuticals, Inc. - CMPI

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Checkmate Pharmaceuticals, Inc. (NasdaqGM:...

CMPI : 10.50 (+0.19%)
REGN : 883.20 (-0.84%)
Rare Poison Pill Strategy an Oddity Among Premium Price Takeover Bids Flurry

USA News Group – Prior to the recent takeover bid of Twitter Inc. (NYSE:TWTR), by the world’s wealthiest man, Elon Musk, the term “poison pill” was rarely uttered in the market. A quick glance...

RHC.AX : 51.460 (-1.79%)
TWTR : 53.70 (+0.66%)
PQEFF : 0.0001 (unch)
KKR : 95.54 (+0.71%)
CMPI : 10.50 (+0.19%)
REGN : 883.20 (-0.84%)
Biotech Stock Roundup: NKTR Plunges on Deal Termination, REGN Offers Update & More

Regulatory and pipeline updates from Nektar (NKTR) and Regeneron (REGN) are a few key highlights from the biotech sector during the past week.

REGN : 883.20 (-0.84%)
BMY : 44.85 (+0.34%)
NKTR : 1.3200 (unch)
AXSM : 71.71 (+0.27%)
CMPI : 10.50 (+0.19%)
Regeneron (REGN) to Buy Checkmate Pharmaceuticals for $250M

Regeneron (REGN) is set to acquire Checkmate Pharmaceuticals for $250 million to broaden its portfolio of diverse immuno-oncology candidates.

REGN : 883.20 (-0.84%)
SNY : 49.13 (-0.47%)
BAYRY : 7.3900 (+1.65%)
CMPI : 10.50 (+0.19%)
Why Adaptimmune Therapeutics, Agenus, and Sorrento Therapeutics Popped Today

Regeneron's buyout of Checkpoint Pharmaceuticals is sparking a rally among clinical-stage cancer research companies today.

ADAP : 1.0750 (+1.42%)
AGEN : 11.69 (+40.84%)
SRNE : 0.0137 (-31.50%)
REGN : 883.20 (-0.84%)
CMPI : 10.50 (+0.19%)
Why Checkmate Pharmaceuticals Stock Is Rocketing Higher Today

Checkpoint Pharmaceuticals lands a premium-rich buyout offer from biotech heavyweight Regeneron.

CMPI : 10.50 (+0.19%)
REGN : 883.20 (-0.84%)
Why Is Arqit Quantum (ARQQ) Stock Down Today?

Former ARQQ employees are calling out the company today

ACC : 65.42 (+0.08%)
CMPI : 10.50 (+0.19%)
ARQQ : 0.4877 (+1.90%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is in highly overbought territory. Beware of a trend reversal.

See More Share

Business Summary

Checkmate Pharmaceuticals Inc. is a clinical stage biotechnology company. It is focused on developing proprietary technology to harness the power of the immune system to combat cancer. The company's product candidate includes CMP-001, which is in clinical stage. Checkmate Pharmaceuticals Inc. is based...

See More

Key Turning Points

3rd Resistance Point 10.53
2nd Resistance Point 10.51
1st Resistance Point 10.51
Last Price 10.50
1st Support Level 10.49
2nd Support Level 10.47
3rd Support Level 10.47

See More

52-Week High 10.50
Last Price 10.50
Fibonacci 61.8% 7.25
Fibonacci 50% 6.25
Fibonacci 38.2% 5.25
52-Week Low 2.00

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar